Crinetics Pharmaceuticals (CRNX) Other Non-Current Liabilities (2024 - 2026)

Crinetics Pharmaceuticals' Other Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $4.9 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 178.78% year-over-year to $4.9 million in Q1 2026; TTM through Mar 2026 was $4.9 million, a 178.78% increase from a year earlier, with the FY2025 full-year figure at $3.2 million, up 290.83% from the prior year.
• Other Non-Current Liabilities grew to $4.9 million in Q1 2026 per CRNX's latest filing, from $3.2 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $4.9 million in Q1 2026 and bottomed at $202000.0 in Q2 2024.
• The 3-year median for Other Non-Current Liabilities is $2.1 million (2025), against an average of $2.1 million.
• Across the five-year window, Other Non-Current Liabilities surged 1055.45% in 2025 and jumped 178.78% in 2026, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $829000.0 in 2024, then soared by 290.83% to $3.2 million in 2025, then surged by 52.04% to $4.9 million in 2026.
• Per Business Quant, the three latest CRNX Other Non-Current Liabilities figures stand at $4.9 million (Q1 2026), $3.2 million (Q4 2025), and $2.9 million (Q3 2025).